Abivax (ABVX) Cash & Equivalents (2021 - 2026)

Abivax's Cash & Equivalents history runs 6 years deep, the most recent figure standing at $558.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 268.44% year-over-year to $558.9 million; the TTM figure through Mar 2026 stood at $558.9 million (up 268.44% YoY), while the FY2025 annual figure was $601.4 million, up 290.32% from the prior year.
• Cash & Equivalents was $558.9 million for Q1 2026 at Abivax, down from $601.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $601.4 million in Q4 2025 to a low of $27.5 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $265.3 million across 5 years, with a median of $271.1 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents sank 60.4% in 2022, then surged 885.88% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $27.5 million in 2022, then jumped by 885.88% to $271.1 million in 2023, then tumbled by 43.16% to $154.1 million in 2024, then soared by 290.32% to $601.4 million in 2025, then dropped by 7.07% to $558.9 million in 2026.
• The last three Cash & Equivalents figures came in at $558.9 million (Q1 2026), $601.4 million (Q4 2025), and $168.6 million (Q3 2025), per Business Quant data.